Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Net Income towards Common Stockholders (2020 - 2023)

Terns Pharmaceuticals' Net Income towards Common Stockholders history spans 4 years, with the latest figure at -$21.0 million for Q4 2023.

  • For Q4 2023, Net Income towards Common Stockholders fell 32.85% year-over-year to -$21.0 million; the TTM value through Dec 2023 reached -$90.2 million, down 49.49%, while the annual FY2025 figure was $610000.0, 100.68% up from the prior year.
  • Net Income towards Common Stockholders reached -$21.0 million in Q4 2023 per TERN's latest filing, up from -$29.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $31.0 million in Q4 2020 to a low of -$29.8 million in Q3 2023.
  • Average Net Income towards Common Stockholders over 4 years is -$12.5 million, with a median of -$13.9 million recorded in 2022.
  • The largest YoY upside for Net Income towards Common Stockholders was 2.11% in 2021 against a maximum downside of 145.93% in 2021.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at $31.0 million in 2020, then crashed by 145.93% to -$14.2 million in 2021, then dropped by 11.09% to -$15.8 million in 2022, then plummeted by 32.85% to -$21.0 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Net Income towards Common Stockholders are -$21.0 million (Q4 2023), -$29.8 million (Q3 2023), and -$17.9 million (Q2 2023).